Fermenta BiotechQ3 FY22

Fermenta Biotech Q3 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹465.5P/E: 29.5Market Cap: ₹1.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • Human Vitamin D3 demand is expected to stabilize at levels higher than pre-pandemic, supported by increasing awareness of its immunity benefits.
  • Animal feed Vitamin D3 volumes showed a 145% increase in Q3 FY22 vs. last year but faced price pressure, indicating volume growth may continue but with cyclical price volatility.
  • German subsidiary started sales in Q3 FY22 with INR 6.1 crores revenue; further growth depends on feed market prices and customer approvals.
  • US subsidiary is expanding human nutrition portfolio to balance animal feed dependence, aiming for 45%-50% human nutrition share in the US market within three years.
  • Premix plant in Kullu (Rs. 40 crores investment) underway to support basket expansion ahead of Saykha plant commissioning.
  • Real estate monetization expected to fund Saykha CAPEX, facilitating manufacturing growth of nutraceutical products.
  • Overall, growth drivers include new capacities, geographic expansion, and product diversification in human nutrition.

See what Fermenta Biotech management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no explicit mention of any current or planned new fundraising through debt or equity in the transcript.
  • The company is focused on monetizing real estate assets, particularly through a structured joint development deal for its Thane land, rather than raising funds through equity or debt.
  • Satish Varma mentions that monetization of real estate will play a large role in funding expansions such as the Saykha CAPEX.
  • The management indicated no immediate plans or discussions about equity or debt fundraising; emphasis is on asset monetization and internal funding.
  • They are also focused on completing ongoing merger processes before any major structural financial moves like a new listing on NSE.

See what Fermenta Biotech management said on order book — free account, 30 seconds.

Capex plans

Yes
  • The company is investing around Rs. 40 crores in a premix plant located in Kullu to expand its product basket, expected to be operational in 8 to 10 months.
  • They plan further expansion through a larger Saykha plant once real estate monetization is sufficiently progressed.
  • Real estate monetization, including the Thane land development deal, is intended to fund future CAPEX especially for the Saykha facility.
  • The Saykha CAPEX has been delayed but is a key growth driver.
  • Management is adopting a dynamic approach, utilizing existing capacities while preparing for Saykha's launch.
  • No immediate involvement in construction or development—the company contributes land and receives developed carpet area in return.
  • Other strategic moves include exploring value addition closer to European or American markets.

Track Fermenta Biotech — get its next earnings analysis in your feed

How does Fermenta Biotech rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisFermenta Biotech
Rev 3Mar 3

How does Fermenta Biotech rank in Pharmaceuticals & Biotechnology?

Compare Fermenta Biotech against every Pharmaceuticals & Biotechnology company (Q3 FY22) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →